Cardiovascular Advances in Research and Opportunities Legacy Act
PL 117-244 (H.R.1193), enacted 12/20/2022

[117th Congress Public Law 244]
[From the U.S. Government Publishing Office]



[[Page 2339]]

    CARDIOVASCULAR ADVANCES IN RESEARCH AND OPPORTUNITIES LEGACY ACT

[[Page 136 STAT. 2340]]

Public Law 117-244
117th Congress

                                 An Act


 
    To amend title IV of the Public Health Service Act to direct the 
Director of the National Institutes of Health, in consultation with the 
Director of the National Heart, Lung, and Blood Institute, to establish 
a program under which the Director of the National Institutes of Health 
  shall support or conduct research on valvular heart disease, and for 
         other purposes. <<NOTE: Dec. 20, 2022 -  [H.R. 1193]>> 

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled, <<NOTE: Cardiovascular 
Advances in Research and Opportunities Legacy Act. 42 USC 201 note.>> 
SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Cardiovascular Advances in Research 
and Opportunities Legacy Act''.
SEC. 2. <<NOTE: 42 USC 285b-9.>>  HHS VALVULAR HEART DISEASE 
                    ACTIVITIES.

    (a) In General.--The Secretary of Health and Human Services 
(referred to in this section as the ``Secretary'') shall, as 
appropriate, continue activities related to research, education, and 
awareness of valvular heart diseases.
    (b) NIH Research Related to Valvular Heart Diseases.--
            (1) In general.--The Director of the National Institutes of 
        Health, in consultation with the Director of the National Heart, 
        Lung, and Blood Institute, may support or conduct research 
        regarding valvular heart diseases.
            (2) Support further research.--In order to improve 
        information on, and understanding of, causation and risk factors 
        for valvular heart diseases, research conducted or supported 
        under this subsection for such diseases may include the 
        following:
                    (A) <<NOTE: Data.>>  Use of advanced technological 
                imaging and other relevant methods to generate data 
                related to valvular heart diseases.
                    (B) <<NOTE: Assessments.>>  Assessing potential risk 
                factors for sudden cardiac arrest or sudden cardiac 
                death from valvular heart diseases.
                    (C) Other activities, as appropriate, in order to 
                improve the availability of information on, and advance 
                research related to, valvular heart diseases.
            (3) <<NOTE: Deadline.>>  Mitral valve prolapse workshop.--
        Not later than 2 years after the date of enactment of this Act, 
        the Director of the National Heart, Lung, and Blood Institute 
        shall, as appropriate, convene a workshop composed of subject 
        matter experts and stakeholders to identify research needs and 
        opportunities to develop recommendations for the identification 
        and treatment of individuals with mitral valve prolapse,

[[Page 136 STAT. 2341]]

        including such individuals who may be at risk for sudden cardiac 
        arrest or sudden cardiac death.

    (c) Prevention Activities to Improve Awareness of Sudden Cardiac 
Death as a Result of Valvular Heart Diseases.--
            (1) <<NOTE: Grants. Contracts.>>  In general.--The Secretary 
        may carry out activities to increase education and awareness of 
        valvular heart diseases in order to reduce the incidence of 
        sudden cardiac death caused by such diseases. The Secretary 
        may--
                    (A) award grants or contracts to public or nonprofit 
                private entities to carry out activities under this 
                subsection; and
                    (B) directly, or through grants or contracts, 
                provide technical assistance with respect to such 
                activities.
            (2) Certain activities.--Upon availability of applicable 
        data, projects carried out under paragraph (1) may include--
                    (A) continuing activities at the Centers for Disease 
                Control and Prevention related to valvular heart 
                diseases;
                    (B) improving the awareness of the public concerning 
                any risk factors for, the symptoms of, and the public 
                health impact of, valvular heart diseases; and
                    (C) enhancing public health data collection and 
                improving the quality of such data, as appropriate, 
                regarding cardiac arrests, including cardiac arrests 
                that occur outside of the hospital.
            (3) Grant prioritization.--The Secretary may, in awarding 
        grants or entering into contracts pursuant to paragraph (1), 
        give priority to entities seeking to carry out projects for 
        populations most impacted by valvular heart diseases.
            (4) Coordination of activities.--The Secretary shall, as 
        appropriate, ensure that activities under this section are 
        coordinated with other agencies and offices of the Department of 
        Health and Human Services that carry out activities regarding 
        valvular heart diseases.
            (5) Best practices.--The Secretary shall, as applicable and 
        appropriate, identify and disseminate best practices for 
        relevant health care providers related to valvular heart 
        diseases.

[[Page 136 STAT. 2342]]

    (d) <<NOTE: Time period.>>  Authorization of Appropriations.--For 
purposes of carrying out this section, there are authorized to be 
appropriated $28,000,000 for each of fiscal years 2023 through 2027.

    Approved December 20, 2022.

LEGISLATIVE HISTORY--H.R. 1193:
---------------------------------------------------------------------------

HOUSE REPORTS: No. 117-212 (Comm. on Energy and Commerce).
CONGRESSIONAL RECORD:
                                                        Vol. 167 (2021):
                                    Dec. 8, considered and passed House.
                                                        Vol. 168 (2022):
                                    Dec. 1, considered and passed 
                                        Senate, amended.
                                    Dec. 5, House concurred in Senate 
                                        amendment.

                                  <all>